Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Clinical trial NCT06211036 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06211036
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Extensive-Stage Small-Cell Lung Cancer Small-Cell Lung Cancer

Start date: 2024-06-05
Primary completion: 2027-07-05
Enrollment: 563

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.